Astec LifeSciences Limited has submitted its quarterly compliance certificate to stock exchanges, fulfilling regulatory requirements under SEBI's depositories framework. The certificate pertains to the quarter ended March 31, 2026, and was filed with both BSE and National Stock Exchange of India Limited on April 10, 2026.

Regulatory Compliance Filing

The compliance certificate was filed pursuant to Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018. Company Secretary and Compliance Officer Tejashree Pradhan signed the submission letter, which was digitally authenticated on April 10, 2026.

Certificate Contents and Confirmations

Bigshare Services Private Limited, serving as the company's Registrar and Share Transfer Agent, issued the compliance certificate dated April 3, 2026. The certificate confirms specific operational details regarding dematerialization activities during the quarter.

According to the certificate signed by Akash Shamal, Authorized Signatory of Bigshare Services:

• No securities were received from depository participants for dematerialization up to March 31, 2026
• No certificates required mutilation or cancellation due to absence of dematerialization requests
• No substitution of depositories' names in the register of members was necessary within the 15-day regulatory timeframe

Stock Exchange Submissions

The compliance certificate was simultaneously submitted to both major Indian stock exchanges where Astec LifeSciences shares are listed.

Company Certifications

Astec LifeSciences maintains multiple international quality and environmental certifications, including ISO 9001:2015 for quality management, ISO 14001:2015 for environmental management, and OHSAS 45001:2018 for occupational health and safety standards. The company also participates in the Responsible Care initiative, demonstrating its commitment to sustainability practices.

The quarterly compliance filing represents part of the company's ongoing regulatory obligations as a publicly listed entity, ensuring transparency in share transfer and dematerialization processes for investor protection.

Astec LifeSciences Limited has announced the successful completion of interest payment on its Non-Convertible Debentures (NCDs), demonstrating its commitment to timely debt servicing obligations. The company informed both BSE and NSE about this development through a regulatory filing dated March 27, 2026.

Interest Payment Details

The company made a substantial interest payment as part of its debt obligations. The payment details showcase the company's financial discipline and adherence to scheduled commitments.

Regulatory Compliance

The intimation was made under Regulations 30 and 57 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. This filing also complies with the Master Circular for issue and listing of Non-Convertible Securities, Securitised Debt Instruments, Security Receipts, Municipal Debt Securities and Commercial Paper dated October 15, 2025.

Payment Status Confirmation

The company confirmed that the interest payment was made successfully without any delays or complications. Key status indicators include:

Corporate Communication

The regulatory filing was signed by Tejashree Pradhan, Company Secretary & Compliance Officer (FCS 7167), and was digitally authenticated on March 27, 2026. The communication was addressed to both BSE Limited (Scrip Code: 533138) and National Stock Exchange of India Limited (Symbol: ASTEC), ensuring comprehensive market disclosure.

This timely interest payment reflects the company's strong financial management and commitment to honoring its debt obligations as scheduled, providing confidence to debenture holders and the broader investment community.